Teva Pharmaceutical Industries is a pharmaceutical company located in Israel, which is part of the Healthcare sector, and is traded under the ticker TEVA on the NYSE exchange.
Teva Pharmaceutical Industries stock last closed at $13.05, up 0.38% from the previous day, and has increased 31.02% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.35 percentage points. Teva Pharmaceutical Industries stock is currently +84.19% from its 52-week low of $7.09, and -2.25% from its 52-week high of $13.35.
As of Feb 22, 2024, there are 1.12B shares of TEVA outstanding. The market cap of TEVA is $14.63B. In the past 24 hours, 7.81M TEVA shares were traded.
How to Buy Teva Pharmaceutical Industries Stock
Not sure how to invest in Teva Pharmaceutical Industries stock? Here's how.
Decide where to buy Teva Pharmaceutical Industries stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you determine where to buy Teva Pharmaceutical Industries stock.
Deposit funds into your brokerage account: Select your method of payment and add your information.
Analyze Teva Pharmaceutical Industries stock: The Teva Pharmaceutical Industries ticker symbol is TEVA. Is Teva Pharmaceutical Industries stock a good investment? Should you buy shares of TEVA? How do TEVA's underlying business fundamentals look? Do top analysts think Teva Pharmaceutical Industries is a good buy? Why has TEVA's stock price moved recently? (Hint: Our stock research website can help you figure out if TEVA is a good stock to buy).
Execute your TEVA buy order: Decide if you will purchase TEVA shares at the current market price or use a limit order to purchase TEVA stock at a specific price.
Get notifications regarding your TEVA investment: Create a watchlist to get the latest news on your investment in Teva Pharmaceutical Industries shares.
Step 1: Decide where to buy Teva Pharmaceutical Industries stock
You need a brokerage account in order to access the NYSE market and buy TEVA shares.
A brokerage account is an investment account that allows you to buy and sell a variety of investments, such as stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
In our opinion, eToro is the best online stock brokerage. eToro gives you:
You can invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to world financial markets: From Technology to Utilities, New York to Tokyo — you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've selected the right brokerage, the next step is to fill out some personal details so you are able to buy TEVA stock today.
TEVA profit margin has gone up from -16.4% to -3.5% in the past year.
There are more short-term assets than short-term liabilities on the TEVA balance sheet.
Failed Financial Due Diligence Checks:
TEVA's operating cash flow of $1.37B allows it to safely service it's debt of $20.15B.
Total TEVA debt is higher than 5 years ago, relative to shareholder equity.
TEVA earnings of $491.00M is not sufficient to cover its interest payments.
TEVA has a relatively high debt to equity ratio of 4.71.
There are more long-term liabilities than short-term assets on the TEVA balance sheet.
Is Teva Pharmaceutical Industries stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 7 sell side analysts who monitor TEVA, the consensus analyst rating on Teva Pharmaceutical Industries is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Latest TEVA Analyst Forecasts
Ashwani Verma, a top 27% analyst from UBS upgrades TEVA to a strong buy rating and raises their TEVA price target from $11.00 to $13.00, on Nov 27, 2023.
Jason Gerberry, a top 14% analyst from Bank of America maintains TEVA with a strong buy rating and raises their TEVA price target from $12.00 to $13.00, on Sep 8, 2023.
Bank of America's Jason Gerberry raised their price target on Teva Pharmaceutical Industries (NYSE: TEVA) by 8.3% from $12 to $13 on 2023/09/08. The analyst maintained their Strong Buy rating on the stock.
Gerberry reported that their update was catalyzed by a deep dive into their Biotech & Pharma (CNS) sector coverage area.
U.S. demand for long-acting injectable treatments for schizophrenia "remains attractive," the analyst told investors.
In fact, recent channel checks by Bank of America with key "opinion leaders 'encouraged'" Gerberry to inform their readers that the recently introduced Uzedy* offers sufficient therapeutic distinction on dose format to acquire momentum.
* From here: Uzedy injection is an extended-release injectable suspension used in adults to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions)
Last year, TEVA revenue was $15.85B. Over the last five year, TEVA's revenue has increased by -2.81% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 33.34%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.